Urology of Central Pennsylvania introduces Cutting Edge Prostate Biopsy with 3D MRI/Ultrasound Fusion Technology
Targeted MRI/Ultrasound Fusion biopsy is the latest technology available in the detection and management of prostate cancer and Urology of Central PA is proud to offer this new standard of care. Using the revolutionary Artemis 3D imaging and navigation system, our physicians are now able to better identify and more accurately biopsy suspicious prostate cancer areas.
The MRI/Ultrasound Fusion (or MR/US Fusion) targeted biopsy procedure starts by using pre-exam MRI prostate images. These images are then fused with real-time ultrasound images to create a detailed 3D high-definition map of the prostate. This allows the physician to accurately target any visible lesions during the biopsy.
According to the American Cancer Society, prostate cancer is the second most common cancer in men after skin cancer, and one in seven men will be diagnosed in his lifetime. Prostate cancer can be a serious disease, but with early detection, most men have a 5 year survival rate of 90%.
Urology of Central PA introduction of the MRI/Ultrasound Fusion Prostate biopsy system is the latest breakthrough option in providing patients with improved diagnosis and accuracy in the detection and treatment of prostate cancer.
Contact Urology of Central PA to learn more and to schedule your annual prostate examination.